Chaudhuri Sarbani 4

What Happened
Sarbani Chaudhuri, Rocket Pharmaceuticals' Chief Commercial & Medical Affairs Officer, was granted equity awards on February 11, 2026: 125,924 restricted stock units (RSUs) and a derivative option covering 189,076 shares. Both grants are reported as acquired at $0 on the Form 4 (i.e., no cash purchase reported).

Key Details

• Transaction date: February 11, 2026; Form 4 filed Feb 13, 2026 (not marked as late).
• Awards: 125,924 RSUs (reported as Award/Acquisition, code A) and a 189,076‑share option (reported as derivative Award/Acquisition, code A). Reported price per share: $0 (grant/award).
• Vesting: For both the RSUs and the option, one‑third vests on February 11, 2027; the remaining shares vest in equal quarterly installments over the following two years. Option vesting is subject to continued employment.
• Footnotes: Holdings include RSUs that convert one‑for‑one into common stock. The option is a right to purchase the stated shares (derivative), per the filing.
• Shares owned after the transaction: not specified in the provided filing details.

Context
These are grants/awards (not open‑market purchases or sales). RSUs convert to common shares when vested; the option gives a right to buy shares as it vests. Grants are common for executive compensation and do not by themselves signal a buy/sell decision. The filing shows the award amounts and vesting schedule but does not indicate any immediate exercise or sale.